Dogwood Flags Going Concern, Cash Only Through Q4 2026
DWTX sits 55% above its 52-week low of $1.28 on light trading volume (0.1× avg).
Summary
Dogwood Therapeutics reported a Q2 net loss of $11.5 million and disclosed a going concern warning, with cash only funding operations into Q4 2026.
Key Events · Earnings and Guidance · DWTX
-
Going Concern Warning
Management states cash of $9.6 million is not sufficient to fund operations for at least 12 months, and substantial doubt exists about the company's ability to continue as a going concern.
-
Cash Runway Through Q4 2026
The company expects cash to fund operations only into the fourth quarter of 2026, requiring additional financing beyond that point.
-
Q2 Net Loss of $11.5M
Net loss was $11.5 million, or $0.34 per share, driven by a $9.2 million IPR&D impairment partially offset by a $2.5 million deferred tax benefit.
-
PRIDCor First Payment
In July 2026, PRIDCor broke escrow and Dogwood received its first $100,000 payment under the license agreement, with $87,750 payable to CVR holders.
Analysis · DWTX · Life Sciences
The 10-Q confirms the Q2 net loss of $11.5 million already reported, but the critical new disclosure is the going concern statement: cash of $9.6 million is insufficient to fund operations for 12 months, and the company must raise capital beyond Q4 2026. This is a first-time formal going concern warning, which materially raises the risk of dilution or failure. The subsequent event of a $100,000 PRIDCor payment is minor but shows the license agreement is beginning to generate cash.
At the time of this filing, DWTX was trading at $1.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.9M. The 52-week trading range was $1.28 to $9.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.